Results 21 to 30 of about 1,085,685 (349)

Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso

International Journal of Infectious Diseases, 2020
Highlights • This is the first study on the co-administration of typhoid conjugate vaccine (TCV) in West Africa.• Co-administration of TCV with routine vaccines in a typhoid-endemic country was successful.• TCV was safely co-administered at 15 months ...
S. Sirima, A. Ouédraogo, N. Barry, M. Siribie, A. Tiono, I. Nebie’, A. Konaté, G. D. Berges, A. Diarra, Moussa Ouedraogo, I. Soulama, Alimatou Héma, Shrimati Datta, Yuanyuan Liang, Elizabeth T. Rotrosen, J. Tracy, Leslie P. Jamka, K. Neuzil, M. Laurens   +18 more
semanticscholar   +1 more source

Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. [PDF]

, 2016
BACKGROUND: People affected with sickle cell disease are at high risk of infection from Haemophilus influenzae type b. Before the implementation of Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a ...
Allali, Slimane, Ballas, Samir K., Chalumeau, Martin, de Montalembert, Mariane, Launay, Odile   +4 more
core   +2 more sources

Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine. [PDF]

, 2018
Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Although this is a vaccine preventable disease, S. pneumoniae still causes over 1 million deaths per year, mainly in children under the age of five.
Abouelhadid, Sherif, Cuccui, Jon, Faustini, Sian E, Herbert, Jenny A, Kay, Emily J, Mitchell, Timothy J, Richter, Alex, Wren, Brendan   +7 more
core   +3 more sources

Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region

Journal of Epidemiology and Global Health, 2019
Facing the availability of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo®, Menactra® and others pending for license) and their recent implementation in Saudi Arabia, experts from 11 countries of the Middle East region met at
Atef Shibl, Haysam Tufenkeji, Mohamed Khalil, Ziad Memish,   +4 more
doaj   +1 more source

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. [PDF]

, 2010
BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa.
French, N, Gilks, CF, Gordon, SB, Longwe, H, Molyneux, ME, Mwafulirwa, G, Mwaiponya, M, Mwalukomo, T, White, SA, Zijlstra, EE   +9 more
core   +4 more sources

Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil. [PDF]

, 2017
BackgroundPneumococcal conjugate vaccines (PCVs) are being used worldwide. A key question is whether the impact of PCVs on pneumonia is similar in low- and high-income populations.
Kürüm, Esra, Lustig, Roger, Schuck-Paim, Cynthia, Shioda, Kayoko, Simonsen, Lone, Taylor, Robert J, Warren, Joshua L, Weinberger, Daniel M   +7 more
core   +2 more sources

Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T cell immunity to tumor antigens

Nature Biotechnology, 2019
Personalized cancer vaccines targeting patient-specific neoantigens are a promising cancer treatment modality; however, neoantigen physicochemical variability can present challenges to manufacturing personalized cancer vaccines in an optimal format for ...
G. Lynn, C. Sedlik, Faezzah Baharom, Yaling Zhu, R. A. Ramirez-Valdez, Vincent L. Coble, Kennedy K. S. Tobin, Sarah R. Nichols, Yaakov Itzkowitz, N. Zaidi, Joshua M. Gammon, Nicolas J. Blobel, Jordan Denizeau, Philippe De La Rochere, Brian J Francica, B. Decker, M. Maciejewski, Justin Cheung, H. Yamane, Margery G. Smelkinson, J. Francica, R. Laga, J. Bernstock, L. Seymour, C. Drake, C. Jewell, O. Lantz, E. Piaggio, A. Ishizuka, R. Seder   +29 more
semanticscholar   +1 more source

Adesão às novas vacinas conjugadas. Vacina anti-meningocócica e anti-pneumocócica.

Acta Médica Portuguesa, 2004
The new conjugate vaccines against group C meningococcal infection and pneumococcal infection were introduced in Portugal in 2001. In 2001/2002, the media published several alarming news on meningococcal disease and there was an increased demand of those
Laurinda De Queirós, Luis Castro, Maria Carmo Ferreira, Guilherme Gonçalves   +3 more
doaj   +1 more source

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong

Human Vaccines & Immunotherapeutics, 2022
Use of pneumococcal conjugate vaccines (PCVs) has greatly reduced the incidence of invasive pneumococcal disease (IPD). V114 (VAXNEUVANCE™, Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc.
Salini Mohanty, Tianyan Hu, GyongSeon Yang, Tsz K Khan, Kwame Owusu-Edusei, Isaya Sukarom   +5 more
doaj   +1 more source

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

Human Vaccines & Immunotherapeutics, 2018
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global ...
A. W. Dretler, N. G. Rouphael, D. S. Stephens   +2 more
doaj   +1 more source